Give me 'Section 3. DEVELOPMENT' for this agreement: Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions.
COLLABORATION AGREEMENT
This Collaboration Agreement ("Agreement"), effective as of June , 2010 (the "Effective Date"), is entered into by and between MacroGenics, Inc., a Delaware corporation with a place of business at 1500 East Gude Drive, Rockville, MD 20850 ("MacroGenics"), and Green Cross Corp., a Korean company with a place of business at 303 Bojeong­Dong, Giheung­Gu, Yongin, 446­770, Korea ("Green Cross"). MacroGenics and Green Cross may be referred to herein individually as a "Party" or collectively as the "Parties."
Recitals:
A. MacroGenics has expertise in, and platforms for, the discovery and development of products for the treatment of patients with cancer, inflammatory and infectious diseases.
B. Green Cross conducts research and development with respect to, and sells, pharmaceutical products.
C. Green Cross and MacroGenics desire to enter into collaboration for the development of MacroGenics' anti­HER2 Antibody known as MGAH22, and if approved for commercialization, the commercialization of a Product in South Korea, all upon the terms and conditions set forth in this Agreement.
D. MacroGenics desires to grant to Green Cross, and Green Cross desires to receive, an exclusive license for all Indications for all pharmaceutical forms of MGAH22 for South Korea, upon the terms and conditions set forth in this Agreement.
In consideration of the foregoing premises and the mutual covenants herein contained, the Parties hereby agree as follows:
Agreement: